Our R&D capabilities include
We quickly produce a range of formulations and run a series of tests to provide data for an early go/no-go decision on whether the drug can be delivered transdermally in a TEPI Patch.
Using our knowledge of the skin and transdermal delivery we formulate TEPI Patches using a large library of pharmaceutically acceptable excipients, including those used to enhance permeation of the drug through the skin.
When the standard excipients don’t provide the target release profile for the drug, we don’t give up, we investigate new excipients and combinations of excipients.
Patch prototyping and manufacture
We carry out experiments at different scales to create TEPI Patch formulations and develop the manufacturing process for each formulation using our in-house pilot plant.
We use HPLC and other quantitative analyses to measure drug uniformity, release, permeation and drug degradation at the temperatures required for patch manufacture.
In vitro diffusion assay (patent pending)
We can rapidly measure the flux of drugs from prototype patches using either Strat-M (a skin mimic) or human skin. We are able to run large studies to find the best formulation within 2-3 months.
Our analytical team use industry standard techniques to develop product-specific tests. We analyse the results to confirm that the patch meets the target product profile.
Development of new adhesives
We are researching novel drug-in-adhesive solutions to enhance our TEPI Patch technology and provide a range of options for new products.